BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38740092)

  • 21. Simultaneous targeting of TGF-β/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion.
    Lan Y; Moustafa M; Knoll M; Xu C; Furkel J; Lazorchak A; Yeung TL; Hasheminasab SM; Jenkins MH; Meister S; Yu H; Schlegel J; Marelli B; Tang Z; Qin G; Klein C; Qi J; Zhou C; Locke G; Krunic D; Derner MG; Schwager C; Fontana RE; Kriegsmann K; Jiang F; Rein K; Kriegsmann M; Debus J; Lo KM; Abdollahi A
    Cancer Cell; 2021 Oct; 39(10):1388-1403.e10. PubMed ID: 34506739
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extracellular Vesicles in Glioblastoma Tumor Microenvironment.
    Yekula A; Yekula A; Muralidharan K; Kang K; Carter BS; Balaj L
    Front Immunol; 2019; 10():3137. PubMed ID: 32038644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. USP8 promotes cancer progression and extracellular vesicle-mediated CD8+ T cell exhaustion by deubiquitinating the TGF-β receptor TβRII.
    Xie F; Zhou X; Li H; Su P; Liu S; Li R; Zou J; Wei X; Pan C; Zhang Z; Zheng M; Liu Z; Meng X; Ovaa H; Ten Dijke P; Zhou F; Zhang L
    EMBO J; 2022 Aug; 41(16):e108791. PubMed ID: 35811497
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TGFβ-derived immune modulatory vaccine: targeting the immunosuppressive and fibrotic tumor microenvironment in a murine model of pancreatic cancer.
    Perez-Penco M; Weis-Banke SE; Schina A; Siersbæk M; Hübbe ML; Jørgensen MA; Lecoq I; Lara de la Torre L; Bendtsen SK; Martinenaite E; Holmström MO; Madsen DH; Donia M; Ødum N; Grøntved L; Andersen MH
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600556
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recruiting T-Cells toward the Brain for Enhanced Glioblastoma Immunotherapeutic Efficacy by Co-Delivery of Cytokines and Immune Checkpoint Antibodies with Macrophage-Membrane-Camouflaged Nanovesicles.
    Xu X; Zhang Z; Du J; Xue Y; Chen X; Zhang J; Yang X; Chang D; Xie J; Ju S
    Adv Mater; 2023 Jun; 35(25):e2209785. PubMed ID: 37101060
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Impact of Oncogenic EGFRvIII on the Proteome of Extracellular Vesicles Released from Glioblastoma Cells.
    Choi D; Montermini L; Kim DK; Meehan B; Roth FP; Rak J
    Mol Cell Proteomics; 2018 Oct; 17(10):1948-1964. PubMed ID: 30006486
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients.
    Paff M; Alexandru-Abrams D; Hsu FP; Bota DA
    Hum Vaccin Immunother; 2014; 10(11):3322-31. PubMed ID: 25625931
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emerging extracellular vesicle-based carriers for glioblastoma diagnosis and therapy.
    Wang J; Liu Y; Liu F; Gan S; Roy S; Hasan I; Zhang B; Guo B
    Nanoscale; 2023 Jul; 15(26):10904-10938. PubMed ID: 37337814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas.
    Zeng J; See AP; Phallen J; Jackson CM; Belcaid Z; Ruzevick J; Durham N; Meyer C; Harris TJ; Albesiano E; Pradilla G; Ford E; Wong J; Hammers HJ; Mathios D; Tyler B; Brem H; Tran PT; Pardoll D; Drake CG; Lim M
    Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):343-9. PubMed ID: 23462419
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Combined Approach Employing Chlorotoxin-Nanovectors and Low Dose Radiation To Reach Infiltrating Tumor Niches in Glioblastoma.
    Tamborini M; Locatelli E; Rasile M; Monaco I; Rodighiero S; Corradini I; Franchini MC; Passoni L; Matteoli M
    ACS Nano; 2016 Feb; 10(2):2509-20. PubMed ID: 26745323
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma.
    Zhang M; Kleber S; Röhrich M; Timke C; Han N; Tuettenberg J; Martin-Villalba A; Debus J; Peschke P; Wirkner U; Lahn M; Huber PE
    Cancer Res; 2011 Dec; 71(23):7155-67. PubMed ID: 22006998
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanism of Extracellular Vesicle Secretion Associated with TGF-β-Dependent Inflammatory Response in the Tumor Microenvironment.
    Bonowicz K; Mikołajczyk K; Faisal I; Qamar M; Steinbrink K; Kleszczyński K; Grzanka A; Gagat M
    Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499660
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy.
    Wang H; Zhou H; Xu J; Lu Y; Ji X; Yao Y; Chao H; Zhang J; Zhang X; Yao S; Wu Y; Wan J
    Cancer Lett; 2021 Jan; 496():134-143. PubMed ID: 33022290
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Baseline extracellular vesicle TGF-β is a predictive biomarker for response to immune checkpoint inhibitors and survival in non-small cell lung cancer.
    de Miguel-Perez D; Russo A; Gunasekaran M; Buemi F; Hester L; Fan X; Carter-Cooper BA; Lapidus RG; Peleg A; Arroyo-Hernández M; Cardona AF; Naing A; Hirsch FR; Mack PC; Kaushal S; Serrano MJ; Adamo V; Arrieta O; Rolfo C
    Cancer; 2023 Feb; 129(4):521-530. PubMed ID: 36484171
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of hyaluronic acid conjugates with immunogenic cell death inducer and CpG for glioblastoma local chemo-immunotherapy elicits an immune response and induces long-term survival.
    Catania G; Rodella G; Vanvarenberg K; Préat V; Malfanti A
    Biomaterials; 2023 Mar; 294():122006. PubMed ID: 36701998
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Breaking through the glioblastoma micro-environment via extracellular vesicles.
    Simon T; Jackson E; Giamas G
    Oncogene; 2020 Jun; 39(23):4477-4490. PubMed ID: 32366909
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment.
    Pearson JRD; Cuzzubbo S; McArthur S; Durrant LG; Adhikaree J; Tinsley CJ; Pockley AG; McArdle SEB
    Front Immunol; 2020; 11():582106. PubMed ID: 33178210
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of heparin to rescue immunosuppressive monocyte reprogramming by glioblastoma-derived extracellular vesicles.
    Himes BT; Fain CE; Tritz ZP; Nesvick CL; Jin-Lee HJ; Geiger PA; Peterson TE; Jung MY; Parney IF
    J Neurosurg; 2023 May; 138(5):1291-1301. PubMed ID: 36115048
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiple Synergistic Effects of the Microglia Membrane-Bionic Nanoplatform on Mediate Tumor Microenvironment Remodeling to Amplify Glioblastoma Immunotherapy.
    Fan Q; Kuang L; Wang B; Yin Y; Dong Z; Tian N; Wang J; Yin T; Wang Y
    ACS Nano; 2024 Jun; 18(22):14469-14486. PubMed ID: 38770948
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances.
    Lind H; Gameiro SR; Jochems C; Donahue RN; Strauss J; Gulley JL; Palena C; Schlom J
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32079617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.